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Background. Obesity and asthma are associated. There is a relationship between lung function impairment and the metabolic
syndrome. Whether this relationship also exists in the morbidly obese patients is still unknown. Hypothesis. Low-grade systemic
inflammation associated with the metabolic syndrome causes inflammation in the lungs and, hence, lung function impairment.
Methods.This is cross-sectional study ofmorbidly obese patients undergoing preoperative screening for bariatric surgery.Metabolic
syndrome was assessed according to the revised NCEP-ATP III criteria. Results. A total of 452 patients were included. Patients with
the metabolic syndrome (𝑛 = 293) had significantly higher blood monocyte (mean 5.3 versus 4.9, 𝑃 = 0.044) and eosinophil
percentages (median 1.0 versus 0.8, 𝑃 = 0.002), while the total leukocyte count did not differ between the groups. The FEV
1
/FVC
ratio was significantly lower in patients with the metabolic syndrome (76.7% versus 78.2%, 𝑃 = 0.032). Blood eosinophils were
associated with FEV
1
/FVC ratio (adj. B −0.113, 𝑃 = 0.018). Conclusion. Although the difference in FEV
1
/FVC ratio between the
groups is relatively small, in this cross-sectional study, and its clinical relevancemay be limited, these data indicate that the presence
of the metabolic syndrome may influence lung function impairment, through the induction of relative eosinophilia.
1. Introduction
Obesity is an increasing worldwide problem that has taken
on epidemic proportions [1]. Cross-sectional studies have
shown a positive association between obesity and asthma [2].
Weight loss in obese asthma patients improved morbidity
and lung function [3]; however, the mechanisms underlying
the relationship between asthma and obesity are unclear. It is
suggested that low-grade systemic inflammation associated
with obesity plays a role.
Themetabolic syndrome is a commonmetabolic disorder
that may result from the increasing prevalence of obesity.
Metabolic syndrome is a cluster of cardiometabolic risk fac-
tors characterized by abdominal obesity, insulin resistance,
and chronic systemic inflammation [4]. Positive associations
with lung function impairment have been reported for com-
ponents of the metabolic syndrome, such as hypertension
[5], type diabetes mellitus [6, 7], low-density lipoprotein
cholesterol [8], and overall obesity [9]. In recent large cohort
studies, it has been shown that there is also a relation-
ship between lung function impairment and the metabolic
syndrome [10–12]. However, all the aforementioned studies
included overweight as well as normal weight subjects and
were therefore not specifically targeted to examine these
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issues in themorbidly obese. Data on the association between
lung function impairment and themetabolic syndrome in the
morbidly obese are limited.
The mechanisms underlying the relationship between
impaired lung function and the metabolic syndrome are
unclear. The chronic low-grade systemic inflammation that
is associated with obesity might explain this relationship.
Our hypothesis is that this low-grade systemic inflammation
causes inflammation in the lungs and, hence, lung function
impairment.
We therefore performed a study to investigate (1) the asso-
ciation between lung function and the metabolic syndrome
in morbidly obese subjects and (2) to determine the effect
of systemic inflammation on the relationship between lung
function impairment and the metabolic syndrome.
2. Methods
2.1. Study Population. The subjects included in this study
were consecutive patients who underwent preoperative
screening for bariatric surgery in the Sint FranciscusGasthuis
in Rotterdam, The Netherlands, between October 2009 and
May 2011. Eligibility criteria for bariatric surgery were age
between 18 and 60 years and body mass index (BMI) either
≥40 kg/m2 or ≥35 kg/m2 combined with the presence of
comorbidity, for example, diabetes mellitus, hypertension, or
proven obstructive sleep apnea syndrome (OSAS). Subjects
underwent baseline physical examinations that included
routine assessment of anthropometry, blood pressure, pul-
monary function, and blood samples.
Height and weight were measured wearing light clothes
and no shoes. Body mass index was calculated as weight (in
kg) divided by height (in m) squared. Abdominal circum-
ference was measured directly to the body surface midway
between the lower rib margin and the ileac crest.
The Epworth Sleepiness Scale questionnaire [13] was used
to assess OSAS and the GERD questionnaire [14] for gastro-
esophageal reflux disease (GERD).
All subjects gave informed consent, and the local ethics
committee (Toetsingscommissie Wetenschappelijk Onder-
zoek Rotterdam e.o, Trial no. NL25637.101.08) approved
the study protocol (The Netherlands Trial Register no.
NTR3204).
2.2. Definition of the Metabolic Syndrome. Metabolic syn-
drome was diagnosed according to the National Cholesterol
Education Program’sAdult Treatment Panel III report (NCEP
ATP-III) criteria when ≥3 of the following 5 risk factors
were present: abdominal obesity, an elevated level of serum
triglycerides, low serum level of high-density lipoprotein
cholesterol (HDL-C), elevated blood pressure, and high
serum glucose level or treatment for any of these disorders
[4].
2.3. Pulmonary Function Tests. Spirometry was performed
with Vmax spirometer (Vmax SensorMedics Viasys, type
Encore 20/22/229/62 Encore, Cardinal Health, USA) before
and after 400 𝜇g of inhaled salbutamol, with subjects in a
sitting position and nose clips in place according to the
American Thoracic Society/European Respiratory Society
statement [15]. All values obtained were related to height,
age, and gender and expressed as percentage of their pre-
dicted value (reference ERS 1993). The pulmonary function
results are prebronchodilator values unless specifically noted.
Exhaled nitric oxide (FeNO) was measured with NIOX
MINO (Aerocrine, Sweden) and expressed in parts per billion
(ppb).
2.4. Clinical Chemistry. Blood was taken by venipuncture
during routine preoperative screening. Laboratory measure-
ments were performed according to standard procedures by
our Department of Clinical Chemistry. Plasma-cholesterol,
HDL-cholesterol, glucose, triglycerides, and CRP were mea-
sured using LX 20 and DxC analyzers (Beckman Coulter,
Miami, FL, USA). LDL-cholesterol was calculated using the
Friedewald formula. Total IgE and specific plasma IgE were
determined with a solid-phase two-step chemiluminescent
immunoassay on the Immulite 2000 (Siemens, Los Angeles,
CA). A positive inhalation screen was defined as at least one
increased amount of specific IgE against one of the following
allergens: Aspergillus fumigatus, house-dust mite, cat, dog,
grass, birch, or herbs. Blood cell counts and 5-part leukocyte
differentiation were determined automatically using LH750
analyzers (Beckman Coulter). HbA1C was determined using
a Tosoh G8 HLC-723 analyzer (Tosoh Bioscience, Tokyo,
Japan). Insulin was measured using radio immunoassay
(RIA) DSL1600 (Diagnostic Systems Laboratories, Webster,
TX, USA). Vitamin D was determined by RIA or chemilu-
minescence (LIA) on Liason analyzers (DiaSorin, Stillwater,
MN, USA).
2.5. Statistical Analyses. Unadjusted between-group compar-
isons were performed using Student’s t test or the Chi-
square test, where appropriate, andMann-WhitneyU test for
nonparametric comparisons (eosinophils). CRP, IgE, insulin,
lipoprotein-a, and vitamin B6 were not normally distributed
(standard error of kurtosis and skewness below−3 or above 3)
and were therefore log transformed. Univariate linear regres-
sion was used to evaluate associations between continuous
variables. Backward linear regression analysis was used to
investigate which component of the metabolic syndrome is
related to the FEV
1
/FVC ratio. Variables associated with
FEV
1
/FVC ratio in univariate analysis at a 𝑃-value of <0.1
were examined in the multiple linear regression analysis.
Since the FEV
1
/FVC ratio as percentage predicted is already
corrected for height, age, and gender, we did not add
these variables to the model. As eosinophils and abdominal
circumference were correlated, we selected only eosinophils
to prevent collinearity. We omitted OSAS because of the
large proportion ofmissing data. All analyses were performed
using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA).
Results were evaluated at 95% confidence interval at a two-
sided 𝑃 < 0.05.
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Table 1: General characteristics of the population included in the study.
No metabolic syndrome (𝑛 = 159) Metabolic syndrome (𝑛 = 293) 𝑃 value
Age (years) 37 ± 11 43 ± 10 <0.0011
BMI (kg/m2) 45.4 ± 6.7 46.0 ± 6.5 0.395
Gender (% female) 87.4% 73.7% 0.0012
Ethnicity (% Caucasian) 80.5% 85.0% 0.222
Smoking 0.152
% never smoked 49% 40%
% stopped smoking 29% 32%
% smokes 22% 28%
Pack years3 6.0 ± 11.2 9.9 ± 14.8 0.003
Abdominal circumference (cm) 126.8 ± 14 134.3 ± 16 <0.001
Systolic blood pressure (mmHg) 136.4 ± 17.9 145.98 ± 16.6 <0.001
Diastolic blood pressure (mmHg) 83.6 ± 11.8 87.83 ± 10.1 <0.001
Comorbidities
Diabetes mellitus 3.8% 30.3% <0.001
Hypertension 18.9% 42.8% <0.001
Hypercholesterolemia 1.9% 21.7% <0.001
Self-reported asthma 19.6% 21.0% 0.723
Use of inhaled corticosteroids 3.8% 5.5% 0.413
1Data presented as mean ± standard deviation, 𝑃 value for Student’s 𝑡 test,
2Data presented as percentage, 𝑃 value for Chi-square test.
3Data were log transformed for statistical analysis.
3. Results
3.1. Subjects. A total of 452 subjects were included in the
study (97 males and 355 females). Also 293 subjects (64.8%)
fulfilled the criteria for metabolic syndrome. Table 1 shows
the general characteristics of the study population. Patients
with the metabolic syndrome were significantly older (mean
43 years), were less often female (73.7%), and had a larger
abdominal circumference in centimeters (mean 134.3 cm)
compared to patients without themetabolic syndrome (mean
37 years, 87.4%, and mean 126.8 cm, resp.).
3.2. Metabolic Syndrome and Blood Parameters. Patients
with the metabolic syndrome did not have a higher total
leukocyte count or neutrophil percentage in the peripheral
blood (𝑃 = 0.253), but they did have a significantly higher
percentage of eosinophils (𝑃 = 0.002) and monocytes (𝑃 =
0.044) compared to patients without the metabolic syndrome
(Table 2). Other parameters of systemic inflammation such as
CRP, Complement C3, andComplement C4 did not show sig-
nificant differences between the two groups (Table 2). There
was no correlation between BMI and eosinophils.We did find
a low, but significant, correlation between eosinophils and
abdominal circumference (Spearman correlation coefficient
0.270, 𝑃 < 0.001) and CRP and abdominal circumference
(Spearman correlation coefficient 0.146, 𝑃 = 0.010).
3.3. Metabolic Syndrome and Pulmonary Function Tests.
The subjects with the metabolic syndrome showed a sig-
nificantly lower FEV
1
/FVC ratio—a measure for bronchial
obstruction—compared to the group without the metabolic
syndrome (76.7% and 78.2%, resp., 𝑃 = 0.032), while no
difference was observed regarding FEV
1
or FVC (Table 3).
Although there was no significant difference in FEF
25–75
between subjects with and without the metabolic syndrome,
the FEF
75
was significantly lower in the metabolic syndrome
group (𝑃 = 0.036). Log transformed FeNO—a measure for
bronchial inflammation—showed no difference between the
two groups.Therewas no correlation betweenBMI andFeNO
and abdominal circumference and FeNO.
3.4. Subgroup Analysis: Self-Reported Asthma. There was no
difference in the prevalence of self-reported asthma between
subjects with or without the metabolic syndrome (21.0% ver-
sus 19.6%, resp.,𝑃 = 0.723). In a subgroup analysis of subjects
with self-reported asthma, we found no significant difference
in the use of inhaled corticosteroids, body mass index, pack
years, FEV
1
(% predicted), FEV
1
/FVC (% predicted), FeNO,
blood eosinophils, or CRP between subjects with or without
the metabolic syndrome (data not shown).
3.5. Subgroup Analysis: Reversibility. In a subgroup analysis
of subjects with and without reversibility (ΔFEV
1
≥ 12%), we
found that only 50%of subjectswith reversibility (𝑛 = 30) had
self-reported asthma. Although subjects with reversibility did
use more often inhaled corticosteroids (13.3% versus 4.4%,
𝑃 = 0.032), there was no significant difference in FeNO,
blood eosinophils, or CRP between subjects with andwithout
the metabolic syndrome.
3.6. Variables Related with FE𝑉
1
/FVC Ratio. Since the FEV
1
/
FVC ratio was the only variable of spirometric function
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Table 2: Comparison of blood parameters between subjects with and without metabolic syndrome.
No metabolic syndrome (𝑛 = 159) Metabolic syndrome (𝑛 = 293) 𝑃 value
Leukocytes (109/L) 8.6 ± 2.3 8.9 ± 2.1 0.2531
Neutrophils (%) 70.1 ± 8.6 68.9 ± 9.1 0.186
Lymphocytes (%) 23.7 ± 7.1 23.8 ± 7.0 0.844
Monocytes (%) 4.9 ± 1.8 5.3 ± 1.9 0.044
Eosinophils (%) 0.82 (0.05–1.07) 1.00 (0.45–1.85) 0.0022
CRP (mg/L)3 9.6 ± 7.4 9.5 ± 8.0 0.865
Cholesterol (mmol/L) 5.2 ± 1.0 5.1 ± 1.1 0.198
HDL-cholesterol (mmol/L) 1.3 ± 0.3 1.1 ± 0.2 <0.001
LDL-cholesterol (mmol/L) 3.5 ± 0.9 3.3 ± 1.1 0.108
Triglyceride (mmol/L) 1.0 ± 0.4 1.6 ± 1.0 <0.001
Glucose (mmol/L) 6.3 ± 1.3 8.2 ± 3.9 <0.001
HbA1C (%) 5.52 ± 0.4 6.4 ± 1.5 <0.001
Insulin (mE/L)3 56.2 ± 58.1 75.0 ± 79.4 <0.001
Vitamin D (nmol/L) 39.5 ± 22.9 38.5 ± 17.7 0.661
IgE (kU/L)3 213.5 ± 479.9 197.8 ± 391.3 0.141
Positive inhalation screen 46.2% 44.0% 0.694
1Data presented as mean ± standard deviation, 𝑃 value for Student’s 𝑡-test.
2Data presented as median (1st–3rd quartiles), 𝑃 value for Mann-Whitney 𝑈 test.
3Data were log transformed for statistical analysis.
Table 3: Pulmonary function test of subjects with and without metabolic syndrome.
No metabolic syndrome (𝑛 = 159) Metabolic syndrome (𝑛 = 293) 𝑃 value
FEV1 (% predicted) 93.0 ± 13.9 91.2 ± 14.5 0.206
3
FVC (% predicted) 100.6 ± 14.0 98.5 ± 14.7 0.206
FEV1/FVC 78.2 ± 6.9 76.7 ± 6.4 0.032
FEF
25–75 (% predicted) 77.4 ± 24.0 73.9 ± 23.3 0.152
Reversibility FEV1 > 12% 6% 7% 0.523
2
FeNO (ppb)1 19.3 ± 22.4 17.6 ± 12.6 0.541
1Data were log transformed before comparison.
2Data presented as percentage, 𝑃 value for Chi-square analysis.
3Data presented as mean ± standard deviation, 𝑃 values for Student 𝑡-test.
FEV1: forced expired volume in 1 second; FVC: forced vital capacity; FEF25–75: forced expiratory flow 25%–75%; TLC: total lung capacity; FeNO: fractional
expiratory nitric oxide.
tests which was different between subjects with and without
the metabolic syndrome and our hypothesis was that the
metabolic syndrome causes a lower FEV
1
/FVC ratio—not
the other way around—we investigated which variables were
related to the FEV
1
/FVC ratio.
There was an association between the peripheral blood
eosinophils percentage and the FEV
1
/FVC ratio (univariate
linear regression coefficient =−0.806,𝑃 = 0.006). Abdominal
circumference and OSAS (Epworth Sleepiness Scale (ESS))
were significantly related to the FEV
1
/FVC ratio (univariate
linear regression analysis), whereas BMI, GERD, CRP and
monocytes were not significantly related to the FEV
1
/FVC
ratio (Table 4). Missing values of ESS were not correlated to
other variables.
Since the metabolic syndrome was associated with the
FEV
1
/FVC ratio, we investigated which of the components
of the metabolic syndrome contributed to this relationship.
Only hypertension was significantly related to FEV
1
/FVC
ratio (regression coefficient = −1.612, 𝑃 = 0.038 in backward
linear regression analysis) (Table 5).
3.7. Multiple Regression Analysis. After correction for the use
of inhaled corticosteroids and the number of pack years,
we found an association between blood eosinophils and the
FEV
1
/FVC ratio (adj. B −0.113, 𝑃 = 0.018) (Table 6).
4. Discussion
This study shows that obese patients with the metabolic
syndrome have a higher proportion of blood monocytes and
eosinophils and a lower FEV
1
/FVC ratio, indicating airway
obstruction, than obese patients without the metabolic syn-
drome. Blood eosinophils (%) in morbidly obese subjects
were related to FEV
1
/FVC, whereas monocytes were not.
After adjustment for multiple variables, the relationship
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Table 4: Univariate linear regression analysis of FEV1/FVC.
Regression coefficient Standard error 𝑃 value2
Monocytes (%) −0.079 0.162 0.626
Eosinophils (%) −0.806 0.290 0.006
CRP (mg/mL) 0.075 0.045 0.098
Abdominal circumference (cm) −0.058 0.021 0.006
Body mass index (kg/m2) 0.041 0.047 0.387
OSAS (Epworth Sleepiness Scale)1 0.311 0.141 0.029
GERD (GERD questionnaire) 0.068 0.157 0.667
1Missing values 𝑛 = 148.
2Data presented as linear regression coefficient, 𝑃 value for simple linear regression analysis.
OSAS: obstructive sleep apnea syndrome; GERD: gastro esophageal reflux disease.
Table 5: Univariate regression analysis of relation of components of metabolic syndrome and FEV1/FVC ratio.
Regression coefficient Standard error 𝑃 value1
Abdominal circumference NA
Hypertriglycemia −1.119 0.739 0.130
Low serum HDL-cholesterol 0.712 0.686 0.300
Hypertension −1.612 0.774 0.038
High serum glucose −0.010 0.753 0.989
1Data presented as linear regression coefficient, 𝑃 value for linear regression analysis.
Abdominal circumference is not applicable, because all patients fulfill the criteria for abdominal circumference according to the NCEP-ATP III criteria for
metabolic syndrome.
Table 6: Multiple regression analysis FEV1/FVC ratio.
Whole group (𝑛 = 408) (Adj 𝑅2 = 0.074)
Regression coefficient 95% CI 𝑃 value
Eosinophils (%) −0.113 −1.247–−0.118 0.018
Use of inhalation
corticosteroids −0.025 −3.635–2.122 0.606
Pack years −0.259 −0.162–−0.076 <0.001
Variables associated with FEV1/FVC ratio in univariate analysis at a 𝑃 value
of <0.1 were examined in the multiple linear regression analysis. Since the
FEV1/FVC ratio as percentage predicted is already corrected for height, age,
and gender, we did not add this variable to the model. As eosinophils and
abdominal circumference are correlated, we selected only one variable to
prevent colinearity. We omitted OSAS because of the large proportion of
missing data.
between FEV
1
/FVC ratio and eosinophils remained intact.
Although the differences are small, it strengthens our hypoth-
esis that the presence of the metabolic syndrome could play
a role in lung function impairment, through the induction
of systemic inflammation, in particular mediated by blood
eosinophils. Whether this also leads to asthma on the long
term still remains to be elucidated.
To our knowledge, this is the first study concerning
lung function and the metabolic syndrome in a cohort of
onlymorbidly obese subjects. Secondly, comorbid conditions
associated with obesity such as OSAS and GERD were taken
into account in the current study. Thirdly, adiposity was not
only assessed with BMI, but also with abdominal circum-
ference. Although one would expect that all our subjects
have the metabolic syndrome, we found a 65% prevalence
of the metabolic syndrome in our group, which corresponds
with 60% of the morbidly obese in the NHANES III cohort
[16].
Various studies have shown that obesity causes a modest
reduction in total lung capacity (TLC) and a larger reduction
in functional residual capacity (FRC) [17]. However, we were
unable to perform a TLC measurement in all subjects to rule
out a restrictive pattern. The FEV
1
/FVC ratio is usually well
preserved in obese subjects, or even increased. This could
explain the high mean FEV
1
/FVC ratio in our subjects, and
therefore we have used the FEV
1
/FVC ratio as a continuous
variable and did not use a cutoff value of 70% predicted.
Furthermore, in contrast to the FEV
1
/FVC, the FEV
1
is
influenced by BMI; hence, our focus is on the FEV
1
/FVC
ratio.
The prevalence of self-reported asthma was similar in the
two groups. We did not perform methacholine-provocation
tests; so, a definitive diagnosis of asthma was often not
possible. Sincemisdiagnosis of asthma is a relevant issue, also
in the obese [18], we felt more comfortable using objective
parameters instead of a presumed diagnosis.
Since the metabolic syndrome was associated with the
FEV
1
/FVC ratio in univariate analysis, we investigated which
of the components of the metabolic syndrome contributed
to this relationship. Hypertension was the only component
that was significantly associated with a reduced FEV
1
/FVC
ratio after multiple backward regression analysis. Hyper-
tension may have the strongest association with systemic
inflammation, as proposed by Irace et al. [19]. We could also
confirm the results of Leone et al. [10] showing that there
6 Journal of Obesity
is indeed a relationship between abdominal circumference
(in cm) and the FEV
1
/FVC ratio. Interestingly, we found a
correlation between blood eosinophil percentage and abdom-
inal circumference, where we found no correlation between
blood eosinophil percentage and BMI, indicating that it is
mainly the place of the fat that matters. This suggests that
the increased abdominal circumference of subjects with the
metabolic syndrome causes the relative eosinophilia.
Obesity is a state of chronic low-grade systemic inflam-
mation. Leukocyte count is considered a marker of systemic
inflammation. Several epidemiological studies have already
noted a relationship between some components of metabolic
syndrome and leukocytes [20, 21]. Several studies showed
an increased eosinophil percentage in obesity [22] or in the
metabolic syndrome [20, 21]. C-reactive protein (CRP) is a
traditional marker of inflammation and is well correlated
with BMI [23]. Even though our study found no difference
in CRP between the two groups—we did not use high-
sensitivity CRP measurements—monocyte and eosinophils
percentage in the blood were higher in those with the
metabolic syndrome. Our study suggests that increased
numbers or circulating eosinophils could be a specific man-
ifestation of the systemic inflammation associated with the
metabolic syndrome.
The question remains why there is relative eosinophilia
in the obese. Traditionally, eosinophils are related to allergic
diseases, asthma, and parasitic infections. The fat tissue is
a source of adipokines, which are considered to play a role
in the low-grade systemic inflammation in obesity [24].
Leptin—mainly produced by adipose tissue—is a proinflam-
matory agent. Serum leptin is markedly increased in obese
humans, correlating to BMI [25]; it activates eosinophils [26]
and increases their survival [27]. Serum leptin levels are
elevated in adults of normal weight with impaired lung func-
tion [28]. Eotaxin is an eosinophil-specific chemokine that is
increased in obesity [29]. Adipocytes produce more eotaxin
when stimulated by leptin [30]. Plasma adiponectin—an anti-
inflammatory hormone—is reversely correlated to BMI [31].
The leptin/adiponectin ratio is a marker of insulin resistance
[32] and the metabolic syndrome [33]. Thus, both leptin and
possibly eotaxin could contribute to relative eosinophilia in
the obese. Unfortunately, we do not have data on leptin,
adiponectin, and eotaxin to further support their role in the
observed eosinophilia.
Another question is whether this relative eosinophilia in
the peripheral blood also has local effects on the bronchial
tissue and causes or enhances the bronchial inflammation
as seen in asthma. Asthma-like symptoms are common in
patients with the metabolic syndrome, and their pulmonary
function is impaired [34, 35]. Although we did find dif-
ferences in pulmonary function between subjects with and
without the metabolic syndrome, there was no difference in
prevalence of self-reported asthma between the two groups.
This is, however, unreliable in the morbidly obese [18]. The
characteristics of airway inflammation in asthma (exhaled
nitric oxide (eNO) and inflammatory cells in induced spu-
tum) have been investigated in obesity and are still subject
to debate. de Winter-de Groot et al. showed that a higher
BMI was associated with a higher eNO in healthy patients
[36]. Several studies have found no—or even an inverse—
relationship between the number of sputum eosinophils and
BMI [37]. We found no difference in eNO between subjects
with and without the metabolic syndrome. Induced sputum
or bronchial biopsies could have helped to solve this question
butwere unfeasible in this study. Since therewas no difference
in the use of inhaled corticosteroids, this could not have
influenced our results of eNO.
Our study includes several limitations. We did not mea-
sure TLC values; so, we were not able to firmly assess a
restrictive lung function pattern. Also, we did not perform
methacholine-provocation tests; so, a definite diagnosis of
asthmawas often not possible.The FEV
1
/FVC ratio, however,
is easy to measure and widely used in clinical practice.
Although the differences in FEV
1
/FVC and eosinophils
between subjects with and without the metabolic syndrome
were small, the difference was significant despite the fact
that our study groups consisted of unselected subjects. There
probably is a selection bias since we only included patients
who were willing to undergo bariatric surgery. It is widely
known that most of the subjects who undergo bariatric
surgery are females. This explains the female predominance
among our subjects. Furthermore, we did not measure
adipocytokines or high-sensitivityCRP. We did not include
a non-obese control group as comparison for low-grade
inflammation, and we cannot fully exclude that smoking
might have contributed to a state of low-grade inflamma-
tion. However, we corrected for smoking in the multiple
regression analysis. Finally, we realize that a cross-sectional
association between metabolic syndrome and lung function
cannot establish causality. However, Naveed et al. [12] have
recently shown that the metabolic syndrome predicts a
steeper FEV
1
decline over time, suggesting that the systemic
inflammation produced by metabolic syndrome may impact
the progression to abnormal lung function in a longitudinally
followed cohort.
In summary, our study shows that there is a small, but sta-
tistically significant, difference in eosinophils and FEV
1
/FVC
between subjects with and without the metabolic syndrome.
After correction for other variables, an association between
blood eosinophils and FEV
1
/FVC remained. Although the
differences we have found were relatively small, it might
support our hypothesis that the presence of the metabolic
syndrome may influence lung function impairment, through
the induction of systemic inflammation, in particular, medi-
ated by blood eosinophils. Further research with a firm
diagnosis of asthma and assessment of peripheral airway
inflammation is necessary. Moreover, in order to establish
causality between the metabolic syndrome and lung function
impairment, longitudinal studies in morbidly obese patients
before and after bariatric surgery are needed.
Abbreviations
BMI: Body mass index
CRP: C-reactive protein
ESS: Epworth Sleepiness Scale
FEF
25–75: Forced expiratory flow 25%–75%
Journal of Obesity 7
FeNO: Fraction of exhaled nitric oxide
FEV
1
: Forced expiratory volume in 1 second
FVC: Forced vital capacity
GERD: Gastroesophageal reflux disease
HDL: High-density lipoprotein
NCEP-APT III: National Cholesterol Education Program’s
Adult Treatment Panel III report
OSAS: Obstructive sleep apnea syndrome.
Conflict of Interests
The authors declare no conflict of interests.
Acknowledgments
The authors wish to thank Mrs. Sandra Reijnhart for editing
the paper. The authors are grateful for the help of all the staff
in the Respiratory Laboratory and members of the Bariatric
Surgery Team at Sint Franciscus Gasthuis. This research
was supported by grants from Foundation of Research
and Development, Department of Internal Medicine, Sint
Franciscus Gasthuis (Stichting Onderzoek en Ontwikkeling
Interne Specialismen Sint Franciscus Gasthuis).
References
[1] WHO, “Obesity and overweight,” Fact Sheet no. 311, 2011,
http://www.who.int/mediacentre/factsheets/fs311/en/index
.html.
[2] E. S. Ford, “The epidemiology of obesity and asthma,” The
Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp.
897–909, 2005.
[3] B. Stenius-Aarniala, T. Poussa, J. Kvarnstro¨m, E. L. Gro¨nlund,
M. Ylikahri, and P.Mustajoki, “Immediate and long term effects
of weight reduction in obese people with asthma: randomised
controlled study,”TheBritishMedical Journal, vol. 320, no. 7238,
pp. 827–832, 2000.
[4] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr.,
and C. Lenfant, “Definition of metabolic syndrome: report of
the national heart, lung, and blood institute/American heart
association conference on scientific issues related to definition,”
Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[5] J. V. Selby, G. D. Friedman, and C. P. Quesenberry Jr., “Precur-
sors of essential hypertension: pulmonary function, heart rate,
uric acid, serum cholesterol, and other serum chemistries,”The
American Journal of Epidemiology, vol. 131, no. 6, pp. 1017–1027,
1990.
[6] E. S. Ford andD.M.Mannino, “Prospective association between
lung function and the incidence of diabetes: findings from the
national health and nutrition examination survey epidemio-
logic follow-up study,” Diabetes Care, vol. 27, no. 12, pp. 2966–
2970, 2004.
[7] H. C. Yeh, N.M. Punjabi, N. Y.Wang et al., “Cross-sectional and
prospective study of lung function in adultswith type 2 diabetes:
the atherosclerosis risk in communities (ARIC) study,”Diabetes
Care, vol. 31, no. 4, pp. 741–746, 2008.
[8] D. J. Cirillo, Y. Agrawal, and P. A. Cassano, “Lipids and
pulmonary function in the third national health and nutrition
examination survey,”TheAmerican Journal of Epidemiology, vol.
155, no. 9, pp. 842–848, 2002.
[9] M. Bottai, F. Pistelli, F. di Pede et al., “Longitudinal changes
of body mass index, spirometry and diffusion in a general
population,” European Respiratory Journal, vol. 20, no. 3, pp.
665–673, 2002.
[10] N. Leone, D. Courbon, F.Thomas et al., “Lung function impair-
ment and metabolic syndrome the critical role of abdominal
obesity,” American Journal of Respiratory and Critical Care
Medicine, vol. 179, no. 6, pp. 509–516, 2009.
[11] W. Y. Lin, C. A. Yao, H. C. Wang, and K. C. Huang, “Impaired
lung function is associated with obesity and metabolic syn-
drome in adults,” Obesity, vol. 14, no. 9, pp. 1654–1661, 2006.
[12] B. Naveed, M. D. Weiden, S. Kwon, E. J. Gracely, A. L. Comfort,
N. Ferrier et al., “Metabolic syndrome biomarkers predict lung
function impairment: a nested case-control study,” American
Journal of Respiratory and Critical Care Medicine, vol. 185, no.
4, pp. 392–399, 2012.
[13] M.W. Johns, “A newmethod for measuring daytime sleepiness:
the epworth sleepiness scale,” Sleep, vol. 14, no. 6, pp. 540–545,
1991.
[14] R. Jones,O. Junghard, J. Dent et al., “Development of theGerdQ,
a tool for the diagnosis and management of gastro-oesophageal
reflux disease in primary care,” Alimentary Pharmacology and
Therapeutics, vol. 30, no. 10, pp. 1030–1038, 2009.
[15] M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation
of spirometry,” European Respiratory Journal, vol. 26, no. 2, pp.
319–338, 2005.
[16] Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon,
and S. B. Heymsfield, “Themetabolic syndrome: prevalence and
associated risk factor findings in the US population from the
third national health and nutrition examination survey, 1988–
1994,” Archives of Internal Medicine, vol. 163, no. 4, pp. 427–436,
2003.
[17] D. A. Beuther, S. T. Weiss, and E. R. Sutherland, “Obesity
and asthma,” American Journal of Respiratory and Critical Care
Medicine, vol. 174, no. 2, pp. 112–119, 2006.
[18] S. D. Aaron, K. L. Vandemheen, L. P. Boulet et al., “Overdiagno-
sis of asthma in obese and nonobese adults,” Canadian Medical
Association Journal, vol. 179, no. 11, pp. 1121–1131, 2008.
[19] C. Irace, C. Cortese, E. Fiaschi et al., “Components of the
metabolic syndrome and carotid atherosclerosis: role of ele-
vated blood pressure,” Hypertension, vol. 45, no. 4, pp. 597–601,
2005.
[20] D. J. Kim, J. H. Noh, B. W. Lee et al., “The associations of
total and differential white blood cell counts with obesity,
hypertension, dyslipidemia and glucose intolerance in a Korean
population,” Journal of KoreanMedical Science, vol. 23, no. 2, pp.
193–198, 2008.
[21] W. S. Shim, H. J. Kim, E. S. Kang et al., “The association of
total and differential white blood cell count with metabolic
syndrome in type 2 diabetic patients,” Diabetes Research and
Clinical Practice, vol. 73, no. 3, pp. 284–291, 2006.
[22] D. R. Cottam, P. A. Schaefer, G. W. Shaftan, L. Velcu, and L. D.
G. Angus, “Effect of surgically-inducedweight loss on leukocyte
indicators of chronic inflammation in morbid obesity,” Obesity
Surgery, vol. 12, no. 3, pp. 335–342, 2002.
[23] M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T.
B. Harris, “Elevated C-reactive protein levels in overweight and
obese adults,” Journal of the American Medical Association, vol.
282, no. 22, pp. 2131–2135, 1999.
[24] T. Ronti, G. Lupattelli, and E. Mannarino, “The endocrine
function of adipose tissue: an update,” Clinical Endocrinology,
vol. 64, no. 4, pp. 355–365, 2006.
8 Journal of Obesity
[25] R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum
immunoreactive-leptin concentrations in normal-weight and
obese humans,”The New England Journal of Medicine, vol. 334,
no. 5, pp. 292–295, 1996.
[26] H. Kato, S. Ueki, R. Kamada et al., “Leptin has a priming effect
on eotaxin-induced human eosinophil chemotaxis,” Interna-
tional Archives of Allergy and Immunology, vol. 155, no. 4, pp.
335–344, 2011.
[27] S. Conus, A. Bruno, and H. U. Simon, “Leptin is an eosinophil
survival factor,”The Journal of Allergy and Clinical Immunology,
vol. 116, no. 6, pp. 1228–1234, 2005.
[28] D. D. Sin and S. F. P. Man, “Impaired lung function and
serum leptin in men and women with normal body weight: a
population based study,” Thorax, vol. 58, no. 8, pp. 695–698,
2003.
[29] A. R. Vasudevan, H. Wu, A. M. Xydakis et al., “Eotaxin and
obesity,” Journal of Clinical Endocrinology and Metabolism, vol.
91, no. 1, pp. 256–261, 2006.
[30] H. J. Kim, C. H. Kim, D. H. Lee et al., “Expression of eotaxin in
3T3-L1 adipocytes and the effects of weight loss in high-fat diet
induced obese mice,”Nutrition Research and Practice, vol. 5, no.
1, pp. 11–19, 2011.
[31] S. Engeli, M. Feldpausch, K. Gorzelniak et al., “Association
between adiponectin and mediators of inflammation in obese
women,” Diabetes, vol. 52, no. 4, pp. 942–947, 2003.
[32] F. M. Finucane, J. Luan, N. J. Wareham et al., “Correlation of the
leptin: adiponectin ratio with measures of insulin resistance in
non-diabetic individuals,”Diabetologia, vol. 52, no. 11, pp. 2345–
2349, 2009.
[33] J. H. Yoon, J. K. Park, S. S. Oh, K.H. Lee, S. K. Kim, I. J. Cho et al.,
“The ratio of serum leptin to adiponectin provides adjunctive
information to the risk of metabolic syndrome beyond the
homeostasis model assessment insulin resistance: the Korean
genomic rural cohort study,” Clinica Chimica Acta, vol. 412, no.
23-24, pp. 2199–2205, 2011.
[34] E. J. Lee, K. H. In, E. S. Ha et al., “Asthma-like symptoms are
increased in the metabolic syndrome,” Journal of Asthma, vol.
46, no. 4, pp. 339–342, 2009.
[35] B. H. Thuesen, L. L. N. Husemoen, L. G. Hersoug, C. Pisinger,
and A. Linneberg, “Insulin resistance as a predictor of incident
asthma-like symptoms in adults,” Clinical and Experimental
Allergy, vol. 39, no. 5, pp. 700–707, 2009.
[36] K. M. de Winter-de Groot, C. K. van der Ent, I. Prins, J. M.
Tersmette, and C. S. P. M. Uiterwaal, “Exhaled nitric oxide: the
missing link between asthma and obesity?” The The Journal of
Allergy and Clinical Immunology, vol. 115, no. 2, pp. 419–420,
2005.
[37] T. J. T. Sutherland, J. O. Cowan, S. Young et al., “The association
between obesity and asthma: interactions between systemic
and airway inflammation,” American Journal of Respiratory and
Critical Care Medicine, vol. 178, no. 5, pp. 469–475, 2008.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
 Computational and  
Mathematical Methods 
in Medicine
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
